Whether Epclusa can cure hepatitis C and the evaluation of the effect of treatment

EpclusaEpclusa, its scientific name is sofosbuvir/velpatasvir Sofosbuvir/Velpatasvir) is a full-genotype oral direct antiviral drug (DAA), developed by Gilead (Gilead). It is widely regarded as a "landmark" drug in the treatment of hepatitis C. It can cover all hepatitis C genotypes 1–6, and can complete treatment without the need for combined interferons, greatly improving patient compliance and cure rates.

The core advantage of Jisandai is its extremely high cure rate (SVR12, which is the sustained virological response rate). A large number of clinical studies and real-world data show that after a complete course of treatment, the cure rate of Jisandai can reach more than 95%, and some studies even show that it exceeds 98%. This means that the vast majority of hepatitis C patients who receive standard treatment are expected to completely eliminate the hepatitis C virus in their bodies and achieve functional cure.

The standard treatment course of Jisandai is usually 12 weeks, taken orally once a day. For patients without cirrhosis or with only compensated cirrhosis, a 12-week course of treatment can achieve a very high cure rate; for some patients who have failed previous treatments or have decompensated cirrhosis, doctors may recommend combining ribavirin or extending the course of treatment to improve the cure rate. In general, the treatment effect of Jisandai is stable and the side effects are mild. The most common ones are mild headache, fatigue and nausea. Most patients can successfully complete the treatment course.

To sum up, Epclusa (Epclusa/Epclusa) can indeed cure hepatitis C in the vast majority of patients. It is an internationally recognized high-efficiency oral regimen for all genotypes. For patients, completing the standard course of treatment, taking medications as prescribed by the doctor, and conducting regular check-ups are the keys to ensuring cure. As Jisandai gradually enters the domestic market and is included in medical insurance, more and more hepatitis C patients can receive treatment at affordable prices, truly realizing the transformation from "chronic virus carriers" to "complete cure".

Reference materials:https://www.drugs.com/